Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | SSTR5 | P35346 | 3/20 | 0.45 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.43 |
| ▸ | CCR3 | P51677 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12852778 | 0.90 | KDM4E (0.46) | KDM4ESMN1; SMN2ALDH1A1MCHR1SSTR5 | |
| SCHEMBL15712239 | 0.90 | SMN1; SMN2 (0.46) | KDM4ESMN1; SMN2ALDH1A1MCHR1SSTR5 | |
| SCHEMBL12852795 | 0.89 | SMN1; SMN2 (0.48) | KDM4ESMN1; SMN2ALDH1A1MCHR1SSTR5 | |
| SCHEMBL1669329 | 0.88 | UTS2R (0.45) | KDM4ESMN1; SMN2ALDH1A1MCHR1SSTR5 | |
| SCHEMBL12852777 | 0.86 | SMN1; SMN2 (0.43) | KDM4ESMN1; SMN2ALDH1A1MCHR1SSTR5 | |
| SCHEMBL13152333 | 0.86 | SMN1; SMN2 (0.43) | KDM4ESMN1; SMN2ALDH1A1MCHR1SSTR5 | |
| SCHEMBL13453086 | 0.84 | TSHR (0.60) | KDM4EMCHR1TSHRSIGMAR1 | |
| SCHEMBL12852793 | 0.82 | KDM4E (0.43) | KDM4ESMN1; SMN2ALDH1A1MCHR1SSTR5 | |
| SCHEMBL4975569 | 0.75 | SIGMAR1 (0.57) | KDM4ESMN1; SMN2ALDH1A1MCHR1SSTR5 | |
| SCHEMBL13453085 | 0.75 | CYP2D6 (0.62) | MCHR1TSHRSIGMAR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9233950-B2 | Co-crystals and salts of CCR3-inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-12 | — | — | US | disclosed |
| US-20150105371-A1 | CO-CRYSTALS AND SALTS OF CCR3-INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-16 | — | — | US | disclosed |
| US-8742115-B2 | Co-crystals and salts of CCR3-inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-03 | — | — | US | disclosed |
| US-20140135307-A1 | CO-CRYSTALS AND SALTS OF CCR3-INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-15 | — | — | US | disclosed |
| US-20120264729-A1 | CO-CRYSTALS AND SALTS OF CCR3-INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264729-A1 | CO-CRYSTALS AND SALTS OF CCR3-INHIBITORS | CCR3, CCR1, CCR4 | KDM4E 4560/4885SMN1; SMN2 3098/4885ALDH1A1 2661/4885 |
| US-20140135307-A1 | CO-CRYSTALS AND SALTS OF CCR3-INHIBITORS | CCR3, CCR1, CCR4 | KDM4E 4560/4885SMN1; SMN2 3098/4885ALDH1A1 2661/4885 |
| US-20150105371-A1 | CO-CRYSTALS AND SALTS OF CCR3-INHIBITORS | CCR3, CCR1, CCR4 | KDM4E 4560/4885SMN1; SMN2 3098/4885ALDH1A1 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.